Literature DB >> 23852939

Cell-penetrating peptides: achievements and challenges in application for cancer treatment.

Meong Cheol Shin1, Jian Zhang, Kyoung Ah Min, Kyuri Lee, Youngro Byun, Allan E David, Huining He, Victor C Yang.   

Abstract

One of the major hurdles to cure cancer lies in the low potency of currently available drugs, which could eventually be solved by using more potent therapeutic macromolecules, such as proteins or genes. However, although these macromolecules possess greater potency inside the cancer cells, the barely permeable cell membrane remains a formidable barrier to exert their efficacy. A widely used strategy is to use cell penetrating peptides (CPPs) to improve their intracellular uptake. Since the discovery of the first CPP, numerous CPPs have been derived from natural or synthesized products. Both in vitro and in vivo studies have demonstrated that those CPPs are highly efficient in transducing cargoes into almost all cell types. Therefore, to date, CPPs have been widely used for intracellular delivery of various cargoes, including peptides, proteins, genes, and even nanoparticles. In addition, recently, based on the successes of CPPs in cellular studies, their applications in vivo have been actively pursued. This review will focus on the advanced applications of CPP-based in vivo delivery of therapeutics (e.g., small molecule drugs, proteins, and genes). In addition, we will highlight certain updated applications of CPPs for intracellular delivery of nanoparticulate drug carriers, as well as several "smart" strategies for tumor targeted delivery of CPP-cargoes.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; cell penetrating peptides; in vivo; macromolecule; nanoparticle

Mesh:

Substances:

Year:  2013        PMID: 23852939      PMCID: PMC3929953          DOI: 10.1002/jbm.a.34859

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  129 in total

Review 1.  Biomaterials: where we have been and where we are going.

Authors:  Buddy D Ratner; Stephanie J Bryant
Journal:  Annu Rev Biomed Eng       Date:  2004       Impact factor: 9.590

2.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

Authors:  R L Juliano; V Ling
Journal:  Biochim Biophys Acta       Date:  1976-11-11

3.  Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A.

Authors:  F Stirpe; S Olsnes; A Pihl
Journal:  J Biol Chem       Date:  1980-07-25       Impact factor: 5.157

4.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

5.  Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo.

Authors:  Carsten Rudolph; Ulrike Schillinger; Aurora Ortiz; Kerstin Tabatt; Christian Plank; Rainer H Müller; Joseph Rosenecker
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

6.  Arginine-mediated RNA recognition: the arginine fork.

Authors:  B J Calnan; B Tidor; S Biancalana; D Hudson; A D Frankel
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

Review 7.  Delivery of bioactive molecules into the cell: the Trojan horse approach.

Authors:  Gunnar P H Dietz; Mathias Bähr
Journal:  Mol Cell Neurosci       Date:  2004-10       Impact factor: 4.314

8.  Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide.

Authors:  L Fisher; U Soomets; V Cortés Toro; L Chilton; Y Jiang; U Langel; K Iverfeldt
Journal:  Gene Ther       Date:  2004-08       Impact factor: 5.250

Review 9.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

10.  Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites.

Authors:  Masahiro Inoue; Mutsuko Mukai; Yukou Hamanaka; Masaharu Tatsuta; Masahiro Hiraoka; Shinae Kizaka-Kondoh
Journal:  Int J Oncol       Date:  2004-09       Impact factor: 5.650

View more
  31 in total

Review 1.  Engineering liposomal nanoparticles for targeted gene therapy.

Authors:  C Zylberberg; K Gaskill; S Pasley; S Matosevic
Journal:  Gene Ther       Date:  2017-05-15       Impact factor: 5.250

2.  Poly-arginine conjugated triarylmethyl radical as intracellular spin label.

Authors:  Benoit Driesschaert; Andrey A Bobko; Timothy D Eubank; Alexandre Samouilov; Valery V Khramtsov; Jay L Zweier
Journal:  Bioorg Med Chem Lett       Date:  2016-02-19       Impact factor: 2.823

Review 3.  Peptide-Based Therapeutics for Oncology.

Authors:  Elizaveta Fisher; Kirill Pavlenko; Alexander Vlasov; Galina Ramenskaya
Journal:  Pharmaceut Med       Date:  2019-02

4.  Transferrin/α-tocopherol modified poly(amidoamine) dendrimers for improved tumor targeting and anticancer activity of paclitaxel.

Authors:  Himanshu Bhatt; Sri Vishnu Kiran Rompicharla; Balaram Ghosh; Vladimir Torchilin; Swati Biswas
Journal:  Nanomedicine (Lond)       Date:  2019-12       Impact factor: 5.307

Review 5.  Advances on Tumor-Targeting Delivery of Cytotoxic Proteins.

Authors:  Akmal M Asrorov; Zeyun Gu; Kyoung Ah Min; Meong Cheol Shin; Yongzhuo Huang
Journal:  ACS Pharmacol Transl Sci       Date:  2019-12-30

Review 6.  Self-assembling peptide-based building blocks in medical applications.

Authors:  Handan Acar; Samanvaya Srivastava; Eun Ji Chung; Mathew R Schnorenberg; John C Barrett; James L LaBelle; Matthew Tirrell
Journal:  Adv Drug Deliv Rev       Date:  2016-08-14       Impact factor: 15.470

7.  Peptide internalization enabled by folding: triple helical cell-penetrating peptides.

Authors:  Aparna Shinde; Katie M Feher; Chloe Hu; Katarzyna Slowinska
Journal:  J Pept Sci       Date:  2014-12-18       Impact factor: 1.905

Review 8.  Toxic proteins application in cancer therapy.

Authors:  Zahra Setayesh-Mehr; Mahdiye Poorsargol
Journal:  Mol Biol Rep       Date:  2021-04-25       Impact factor: 2.316

9.  PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.

Authors:  Meong Cheol Shin; Jian Zhang; Kyoung Ah Min; Huining He; Allan E David; Yongzhuo Huang; Victor C Yang
Journal:  Pharm Res       Date:  2015-02-21       Impact factor: 4.200

10.  Structural and Thermodynamic Insight into Spontaneous Membrane-Translocating Peptides Across Model PC/PG Lipid Bilayers.

Authors:  Yuan Hu; Sandeep Patel
Journal:  J Membr Biol       Date:  2014-07-10       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.